Candela Launches Exceed Medical Microneedling System image

Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM's medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch in the United States. The agreement may be expanded with additional products in the future.  

The Exceed system from MT.DERM, powered by its brand amiea med, is the only dual-indicated, FDA-cleared medical microneedling device. The German-engineered device is clinically proven to dramatically reduce the appearance of facial wrinkles and facial acne scars. It is also CE registered in Europe.

Candela manufactures and distributes the Profound system - the only real-time, temperature-controlled, long pulse radiofrequency (RF) microneedling device.  With the Exceed medical microneedling system, Candela further enhances its existing microneedling portfolio and positions the company for expanded market penetration.

"We are delighted to enter into a partnership with MT.DERM, based on their superior engineering and deep understanding of needling technology" says Geoffrey Crouse, CEO of Candela.  "Microneedling is an essential component of any medical aesthetics practice.  The addition of the Exceed medical microneedling system strengthens Candela's product portfolio, which continues to provide customers the most comprehensive offering of best-in-class medical aesthetic technologies."

"MT.DERM's value of quality and engineering excellence, partnered with Candela's commitment to "Science, Results, Trust" along with their global customer support capability and commercial strength make this an ideal partnership for us," adds Joern Kluge, founder and CEO of MT.DERM. "Candela and MT.DERM jointly have the industry experience and reputation to make the Exceed device a leader in the mechanical microneedling global market."

The Candela Exceed system will be available for in-office treatments by a licensed medical professional beginning in January 2020.